Glaxo, Boehringer Ingelheim Agree to Expand Anti-HIV Licensing in South Africa

Law360 (December 10, 2003, 12:00 AM EST) -- GlaxoSmithKline and Boehringer Ingelheim agreed to allow the widespread manufacture of generic versions of their patented AIDS drugs in South Africa, according to news reports.

In an out-of-court settlement with the country's Treatment Action Campaign (TAC), the companies on Wednesday said they would grant more licences to generic firms to produce and import antiretroviral drugs which fight the spread of the HIV virus.

South Africa has more people living with HIV/AIDS than any other country in the world: an estimated 5.3 million, equal to to 13%...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.